Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...

Kymera Therapeutics, Inc. KYMR announced its business goals for 2025, along with anticipated progress on its pipeline of ...

A statement from Gilead indicates that the deal is likely to lower its 2025 GAAP and non-GAAP earnings per share by $0.15 to ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

These next-generation STAT6 inhibitors demonstrate excellent oral bioavailability, cell permeability, and metabolic stability, and do not target STAT6 for degradation. DeepCure expects to select a ...

Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25Kymera plans to initiate a KT-621 Phase 1b trial in atopic ...

Gilead Sciences’ inflammation drug prospects have come via deals, and the latest one brings drug candidates for an elusive target that’s in pursuit by a growing number of companies. The ...

Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...

Gilead Sciences Inc. and LEO Pharma have partnered to accelerate the development and commercialization of LEO Pharma’s small ...